Evidence map›Paper›PMID 38402342›Full record

Trial reportBritish journal of cancer2024

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.

C S Karapetis, H Liu, M J Sorich, L D Pederson, E Van Cutsem, T Maughan, J Y Douillard, C J O'Callaghan, D Jonker, C Bokemeyer and 10 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 9 countries.

C S KarapetisFlinders Medical Centre, Adelaide, SA, Australia. c.karapetis@flinders.edu.au.ORCID 0000-0003-1741-996X
H LiuMayo Clinic, Rochester, NY, USA.
M J SorichFlinders University, Adelaide, SA, Australia.ORCID 0000-0003-1999-866X
L D PedersonMayo Clinic, Rochester, NY, USA.
E Van CutsemUniversity Hospitals Gasthuisberg Leuven and University of Leuven, Leuven, Belgium.ORCID 0000-0002-6372-1230
T MaughanUniversity of Liverpool, Liverpool, UK.ORCID 0000-0002-0580-5065
J Y DouillardUniversity of Nantes and Integrated Centers of Oncology ICO Rene Gauducheau Cancer Nantes, Nantes, France.
C J O'CallaghanCanadian Cancer Trials Group, Kingston, ON, Canada.
D JonkerThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
C BokemeyerUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
A SobreroOspedale San Martino, Genova, Italy.
C CremoliniUniversity of Pisa, Pisa, Italy.ORCID 0000-0002-0520-4841
B ChibaudelFranco-British Institute Levallois-Perre, Levallois-Perre, France.
J ZalcbergDept of Medical Oncology, Alfred Health and School of Public Health, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-6624-0782
R AdamsVelindre Cancer Centre Cardiff University, Cardiff, UK.
M BuyseInternational Drug Development Institute, Louvain-la-Neuve, Belgium.
M PeetersAntwerp University and Antwerp University Hospital, Antwerp, Belgium.
T YoshinoNational Cancer Centre Hospital East, Kashiwa, Japan.ORCID 0000-0002-0489-4756
A de GramontFranco-British Institute Levallois-Perre, Levallois-Perre, France.
Q ShiMayo Clinic, Rochester, NY, USA.
Mayo Clinic in Florida · USFlinders University · AUInstitut Hospitalier Franco Britannique · FRAlfred Health · AUAntwerp University Hospital · BECentre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers · FRInternational Drug Development Institute (Belgium) · BENational Cancer Centre Japan · JPOspedale Policlinico San Martino · ITOttawa Hospital · CAUniversitair Ziekenhuis Leuven · BEUniversität Hamburg · DEUniversity of Liverpool · GBUniversity of Pisa · ITVelindre Cancer Centre · GB

Funding

Department of Health | National Health and Medical Research Council (NHMRC) 1085364
6 · The paper itself

Abstract

backgroundKRAS mutations in metastatic colorectal cancer (mCRC) are used as predictive biomarkers to select therapy with EGFR monoclonal antibodies (mAbs). Other factors may be significant determinants of benefit.

methodsIndividual patient data from randomised trials with a head-to-head comparison between EGFR mAb versus no EGFR mAb (chemotherapy alone or best supportive care) in mCRC, across all lines of therapy, were pooled. Overall survival (OS) and progression-free survival (PFS) were compared between groups. Treatment effects within the predefined KRAS biomarker subsets were estimated by adjusted hazard ratio (HR

results5675 patients from 8 studies were included, all with known mCRC KRAS mutation status. OS (HR

conclusionThe benefit provided by EGFR mAbs in KRAS WT mCRC is associated with left-sided primary tumour location, younger patient age and absence of NRAS or BRAF mutations. Survival benefit is observed with fluorouracil but not capecitabine. Exploratory results support further research in KRAS mutant mCRC without liver metastases.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsLiver NeoplasmsRectal NeoplasmsAntibodies, MonoclonalCetuximabErbB ReceptorsFluorouracilHumansMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Antibodies, MonoclonalCetuximabEGFR protein, humanErbB ReceptorsFluorouracilProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)

Identifiers

PMID38402342
PMCPMC11015038
OpenAlexW4392139117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.